RecruitingPhase 1NCT06538181
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Studying VEXAS syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Meagan A Jacoby, M.D., Ph.D.Washington University School of Medicine
- Intervention
- Pacritinib(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Washington University School of Medicine, St Louis, Missouri, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06538181 on ClinicalTrials.govOther trials for VEXAS syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07102849Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research StudyNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE2NCT06782373A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Swedish Orphan Biovitrum
- RECRUITINGNCT06657846HRQoL and Financial Toxicity in Patients With VEXAS SyndromeGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGNCT06377462Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial CollectionTechnische Universität Dresden